Allergan

AbbVie nears Allergan lockup with EU antitrust approval—and only one selloff required
AbbVie nears Allergan lockup with EU antitrust approval—and only one selloff required
Fierce Pharma
AbbVie
Allergan
antitrust
M&A
brazikumab
Europe
Flag link:
A big finish confirms 2019 as a takeover year to remember
A big finish confirms 2019 as a takeover year to remember
EP Vantage
M&A
AbbVie
Allergan
Astellas
Bristol-Myers Squibb
Eli Lilly
Merck
Novartis
Pfizer
Sanofi
Flag link:
AbbVie answers Allergan aesthetics worries with separate new unit
AbbVie answers Allergan aesthetics worries with separate new unit
Fierce Pharma
AbbVie
Allergan
aesthetics
M&A
Allergan Aesthetics
Flag link:
Overview: CRISPR Technology Headed to Clinical Trials
Overview: CRISPR Technology Headed to Clinical Trials
BioSpace
CRISPR
Editas Medicine
clinical trials
Allergan
LCA10
Flag link:
Should AbbVie break up Allergan? If it wants to make up for Humira, then yes, analyst says
Should AbbVie break up Allergan? If it wants to make up for Humira, then yes, analyst says
Fierce Pharma
AbbVie
Allergan
M&A
Humira
Botox
Flag link:
In last-minute deal, Allergan forks over a hefty $300M to settle pay-for-delay dispute
In last-minute deal, Allergan forks over a hefty $300M to settle pay-for-delay dispute
Fierce Pharma
AbbVie
Allergan
M&A
pay-for-delay
Warner Chilcott
Watson Pharmaceuticals
Flag link:
Novartis, Merck and Allergan raise drug prices to start 2020, joining Big Pharma peers
Novartis, Merck and Allergan raise drug prices to start 2020, joining Big Pharma peers
Fierce Pharma
drug pricing
Merck
Allergan
Novartis
Flag link:
Top Biopharma M&As in 2019
Top Biopharma M&As in 2019
BioSpace
M&A
Bristol-Myers Squibb
Celgene
AbbVie
Allergan
Roche
Spark Therapeutics
Novartis
The Medicines Company
Alkermes
Rodin Therapeutics
Sumitomo Dainippon
Roivant
Flag link:
Allergan scores year-end FDA nod for CGRP migraine med Ubrelvy, plans early 2020 launch
Allergan scores year-end FDA nod for CGRP migraine med Ubrelvy, plans early 2020 launch
Fierce Pharma
Allergan
UIbrelvy
ubrogepant
FDA
migraines
CGRPs
Flag link:
Amgen, Allergan join Rituxan biosimilar challenge with FDA filing
Amgen, Allergan join Rituxan biosimilar challenge with FDA filing
Pharmaforum
Amgen
Allergan
biosimilar
Roche
Rituxan
Flag link:
After big M&A year, will pharma move away from massive deals in 2020?
After big M&A year, will pharma move away from massive deals in 2020?
Fierce Pharma
M&A
Sanofi
Merck
AbbVie
Allergan
Bristol-Myers Squibb
Celgene
FTC
Flag link:
3 Biotechs Facing FDA Approvals by Year's End
3 Biotechs Facing FDA Approvals by Year's End
Motley Fool
FDA
Amgen
Vascepa
Allergan
migraines
ubrogepant
Intra-Cellular Therapies
lumateperone
schizophrenia
Flag link:
Go or no go? Vascepa’s finale and Allergan's pain relief
Go or no go? Vascepa’s finale and Allergan's pain relief
EP Vantage
FDA
Amarin
Vascepa
Allergan
migraines
ubrogepant
Flag link:
Before 2019 closes, the FDA has 3 key approval decisions to make
Before 2019 closes, the FDA has 3 key approval decisions to make
Biopharma Dive
Allergan
ubrogepant
migraines
Amarin
Vascepa
Intra-Cellular Therapeutics
lumateperone
schizophrenia
bipolar disorder
drug approvals
FDA
Flag link:
AbbVie's new launches Skyrizi, Rinvoq aren't getting enough credit: analyst
AbbVie's new launches Skyrizi, Rinvoq aren't getting enough credit: analyst
Fierce Pharma
AbbVie
Skyrizi
Rinvoq
Allergan
drug launches
Flag link:
AbbVie Shareholders Have a Lot to Look Forward To With Allergan
AbbVie Shareholders Have a Lot to Look Forward To With Allergan
Motley Fool
AbbVie
Allergan
earnings
M&A
Flag link:
Allergan builds case for migraine drug ubrogepant as FDA verdict nears
Allergan builds case for migraine drug ubrogepant as FDA verdict nears
Pharmaforum
Allergan
migraines
ubrogepant
FDA
Flag link:
Top 10 pharma settlements since 2018
Top 10 pharma settlements since 2018
Fierce Pharma
settlements
Reckitt Benckiser
JNJ
Bayer
Allergan
Actelion
Purdue Pharma
Teva Pharmaceutical
Endo
Teikoku
Insys
Pfizer
GSK
Astellas
Amgen
Flag link:
Allergan enlists Exicure in search of hair loss drugs with $25M upfront, doubling down on area dear to AbbVie
Allergan enlists Exicure in search of hair loss drugs with $25M upfront, doubling down on area dear to AbbVie
Endpoints
Allergan
AbbVie
R&D
hair loss
Exicure
Flag link:
With Allergan megamerger looming, AbbVie plots massive $28B bond offering: Bloomberg
With Allergan megamerger looming, AbbVie plots massive $28B bond offering: Bloomberg
Fierce Pharma
AbbVie
Allergan
M&A
Flag link:

Pages